Dapagliflozin effective from clinical standpoint as well as cost standpoint for CKD patients

The burden of chronic kidney disease (CKD) to both healthcare systems and patients is considerable. Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, was shown to be an efficacious treatment for CKD in the Dapagliflozin And Prevention of Adverse outcomes in CKD (DAPA-CKD) trial.

Researchers have revealed in a new analysis that in patients eligible for the DAPA-CKD trial, dapagliflozin is not only effective from a clinical standpoint, but also from a cost standpoint.

The recent analysis put forth by researchers has been published in the Clinical Journal of American Society of Nephrology

The DAPA-CKD trial showed treatment with dapagliflozin and standard of care led to a slowing of decline in kidney function and a reduction in the incidence of kidney failure and risk of cardiovascular- or kidney-related death, compared with placebo and standard of care. In this latest analysis, Phil McEwan, PhD (Health Economics and Outcomes Research Ltd., Cardiff, UK) and his colleagues estimated the cost-effectiveness of dapagliflozin added to standard therapy, compared with standard therapy alone, based on the results of the DAPA-CKD trial and considered from a multinational European healthcare system perspective.